Summary
The SCOUT study is a multicenter, placebo-controlled, double-blind randomized controlled trial conducted to evaluate if a shorter 5-day course of antibiotics is non-inferior to a standard 10-day course of antibiotics in children with urinary tract infection (UTI) [1]. The eligible population included children aged 2 months to 10 years who were being treated for UTI with one of the five chosen antibiotics (amoxicillin-clavulanate, cefixime, cefdinir, cephalexin, or trimethoprim-sulfamethoxazole) and have become afebrile and free of symptoms of UTI after 5 days of therapy. At this time point, the eligible children were randomized to either the short-course arm, in which antibiotics were replaced by a matching placebo or the standard-course arm, in which antibiotics were continued. The study drugs (placebo or antibiotics) were continued to complete 10 days of therapy. The study’s primary outcome was the recurrence of symptomatic UTI between two hospital visits - first on day 6 i.e., at the time of randomization, and second between days 11 and 14. A definition with high specificity was used to identify the primary outcome and included three criteria: symptoms, pyuria, and positive urine culture. Secondary outcomes included the individual components of the primary outcome, and UTI between days 11–14 and days 38–44. The study also reported the adverse effects of the drugs and the incidence of gastrointestinal colonization with resistant organisms. The sample size was calculated for investigating the non-inferiority of the shorter antibiotic course. The study was powered to detect a non-inferiority margin of 5%. This meant that if the baseline incidence of treatment failure with the use of a standard course of antibiotics was 5%, investigators were willing to accept a treatment failure rate of 10% in the shorter antibiotic course to consider it as a ‘clinically’ non-inferior therapy. The primary analysis was conducted following the intention-to-treat (ITT) principle. The primary outcome was observed in 14 (4.2%) children in the short-course group and 2 (0.6%) children in the standard-course group. The upper margin of the confidence interval of the risk difference was 5.5%. As this was more than the preset non-inferiority margin of 5%, the non-inferiority of the short-course therapy could not be proven. Children randomized to the short-course therapy were also more likely to have asymptomatic bacteriuria and a positive urine culture. The two study groups had similar rates of adverse events and antimicrobial resistance of stool flora. The authors concluded that although the non-inferiority could not be proven, given the low incidence of failure (i.e., recurrence of symptomatic UTI) with the short-course therapy, the latter can be a reasonable option in children with UTI who show improvement after 5 days of antibiotics.
References
Zaoutis T, Shaikh N, Fisher BT, et al. Short-course therapy for urinary tract infections in children. JAMA Pediatr. 2023 Jun 26:e231979. Epub ahead of print.
US Department of Health and Human Services, Administration F and D, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Non-Inferiority Clinical Trials to Establish Effectiveness - Guidance for Industry. 2016. Accessed July 23, 2023. Available from: https://www.fda.gov/media/78504/download
Kaji AH, Lewis RJ. Non-inferiority trials: is a new treatment almost as effective as another? JAMA. 2015;313:2371–2.
Fergusson D, Aaron SD, Guyatt G, Hébert P. Post-randomization exclusions: the intention to treat principle and excluding patients from analysis. BMJ. 2002;325:652.
Sugianli AK, Ginting F, Parwati I, Jong MD de, Leth F van, Schultsz C. Antimicrobial resistance among uropathogens in the Asia-Pacific region: a systematic review. JAC-Antimicrob Resist. 2021;3:dlab003.
References
Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J. 2008;27:302–8.
Becknell B, Schober M, Korbel L, Spencer JD. The diagnosis, evaluation and treatment of acute and recurrent pediatric urinary tract infections. Expert Rev Anti-Infect Ther. 2015;13: 81–90.
Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol 2012; 27:363–73.
Zaoutis T, Shaikh N, Fisher BT, et al. Short-course therapy for urinary tract infections in children: the SCOUT randomized clinical trial. JAMA Pediatr. 2023 Jun 26:e231979 [epub ahead of print].
Shaikh N, Haralam MA, Kurs-Lasky M, Hoberman A. Association of renal scarring with number of febrile urinary tract infections in children. JAMA Pediatr. 2019;173:949–52.
National Institute for Health and Care Excellence. Urinary tract infection in under 16s: diagnosis and management (NICE guideline 224). 2022. Accessed 20 July, 2023. Available from: https://www.nice.org.uk/guidance/ng224/resources/urinarytract-infection-in-under-16s-diagnosis-and-management-pdf-66143835667141
Buettcher M, Trueck J, Niederer-Loher A, et al. Swiss Consensus Recommendations on Urinary Tract Infections in Children. Eur J Pediatr. 2021;180:663–74.
Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management; Roberts KB. Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months. Pediatrics. 2011;128:595–610.
Robinson JL, Finlay JC, Lang ME, Bortolussi R; Canadian Paediatric Society, Infectious Diseases and Immunization Committee, Community Paediatrics Committee. Urinary Tract Infections in Infants and Children: Diagnosis and Management. Paediatr Child Health. 2014;19:315–25.
Daniel M, Szajewska H, Pañczyk-Tomaszewska M. 7-day compared with 10-day antibiotic treatment for febrile urinary tract infections in children: protocol of a randomised controlled trial. BMJ Open. 2018;8:e019479.
Sethi N, Carlsen ELM, Schmidt IM, Cortes D, Nygaard U, Sehested LT. Individualised versus standard duration of antibiotic therapy in children with acute uncomplicated febrile urinary tract infection: a study protocol and statistical analysis plan for a multicentre randomised clinical trial. BMJ Open. 2023;13:e070888.
References
Yang SS, Tsai J-D, Kanematsu A, Han C-H. Asian Guidelines for Urinary Tract Infection in Children. J Infect Chemother. 2021;27:1543–54.
’t Hoen LA, Bogaert G, Radmayr C, et al. Update of the EAU/ESPU Guidelines on Urinary Tract Infections in Children. J Pediatr Urol. 2021;17:200–7.
Buettcher M, Trueck J, Niederer-Loher A, et al. Swiss Consensus Recommendations on Urinary Tract Infections in Children. Eur J Pediatr. 2021;180:663–74.
Moustafa BH, Rabie MM, El Hakim IZ, et al. Egyptian Pediatric Clinical Practice Guidelines for Urinary Tract Infections in Infants and Children (Evidence Based). Egyptian Pediatric Association Gazette. 2021;69:43.
Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management; Roberts KB. Urinary tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months. Pediatrics. 2011;128:595–610.
Bagga A, Babu K, Kanitkar M, Srivastava R, Pediatrics IPNGIAo. Consensus Statement on Management of Urinary Tract Infections. Indian Pediatr. 2001;38:1106–15.
Michael M, Hodson EM, Craig JC, Martin S, Moyer VA. Short compared with standard duration of antibiotic treatment for urinary tract infection: a systematic review of randomised controlled trials. Arch Dis Child. 2002;87:118–23.
Fitzgerald A, Mori R, Lakhanpaul M, Tullus K. Antibiotics for treating lower urinary tract infection in children. Cochrane Database of Systematic Reviews. 2012;8:CD006857.
Fox MT, Amoah J, Hsu AJ, Herzke CA, Gerber JS, Tamma PD. Comparative effectiveness of antibiotic treatment duration in children with pyelonephritis. JAMA Network Open. 2020;3:e203951.
Desai S, Aronson PL, Shabanova V, et al. Parenteral antibiotic therapy duration in young infants with bacteremic urinary tract infections. Pediatrics. 2019;144:e20183844.
Zaoutis T, Shaikh N, Fisher BT, et al. Short-course therapy for urinary tract infections in children: the SCOUT randomized clinical trial. JAMA Pediatr. 2023;177:782–9.
Funding
Funding: None
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests: None stated.
Rights and permissions
About this article
Cite this article
Chawla, D., Krishnasamy, S. & Ranjan, S. Short-Course Therapy for Pediatric Urinary Tract Infections. Indian Pediatr 60, 762–766 (2023). https://doi.org/10.1007/s13312-023-2993-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-023-2993-8